These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 15969890)

  • 1. Comparative analytical characterization of two commercial human follicle-stimulating hormones extracted from human urine.
    Bassett R; Ceccarelli D; Crisci C; di Tria AM; Mancinelli M; Martelli F; Mendola D; Pezzotti A
    Curr Med Res Opin; 2005 Jun; 21(6):899-905. PubMed ID: 15969890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative characterisation of a commercial human chorionic gonadotrophin extracted from human urine with a commercial recombinant human chorionic gonadotrophin.
    Bassett R; De Bellis C; Chiacchiarini L; Mendola D; Micangeli E; Minari K; Grimaldi L; Mancinelli M; Mastrangeli R; Bucci R
    Curr Med Res Opin; 2005 Dec; 21(12):1969-76. PubMed ID: 16368048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the nature of the follicle-stimulating signal delivered to the ovary during exogenously controlled follicular maturation. A search into the immunological and biological attributes and the molecular composition of two preparations of urofollitropin.
    Ulloa-Aguirre A; Zambrano E; Timossi C; Olivares A; Quintanar A; Aguinaga M; Díaz-Cueto L; Méndez JP
    Arch Med Res; 1995; 26 Spec No():S219-30. PubMed ID: 8845653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF.
    Ziebe S; Lundin K; Janssens R; Helmgaard L; Arce JC;
    Hum Reprod; 2007 Sep; 22(9):2404-13. PubMed ID: 17640944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic analyses of recombinant human follicle-stimulating hormone and urinary-derived gonadotropin preparations.
    Kuwabara Y; Mine K; Katayama A; Inagawa T; Akira S; Takeshita T
    J Reprod Med; 2009 Aug; 54(8):459-66. PubMed ID: 19769189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
    Smitz J; Andersen AN; Devroey P; Arce JC;
    Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins.
    Giudice E; Crisci C; Eshkol A; Papoian R
    Hum Reprod; 1994 Dec; 9(12):2291-9. PubMed ID: 7714147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical identification of additional impurities in urinary-derived gonadotrophins.
    Bassett R; Lispi M; Ceccarelli D; Grimaldi L; Mancinelli M; Martelli F; Van Dorsselaer A
    Reprod Biomed Online; 2009 Sep; 19(3):300-13. PubMed ID: 19778474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.
    Andersen AN; Devroey P; Arce JC
    Hum Reprod; 2006 Dec; 21(12):3217-27. PubMed ID: 16873892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin.
    Grøndahl ML; Borup R; Lee YB; Myrhøj V; Meinertz H; Sørensen S
    Fertil Steril; 2009 May; 91(5):1820-30. PubMed ID: 18439596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study.
    Platteau P; Andersen AN; Balen A; Devroey P; Sørensen P; Helmgaard L; Arce JC;
    Hum Reprod; 2006 Jul; 21(7):1798-804. PubMed ID: 16571641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin alpha).
    Lispi M; Bassett R; Crisci C; Mancinelli M; Martelli F; Ceccarelli D; De Bellis C; Mendola D
    Reprod Biomed Online; 2006 Aug; 13(2):179-93. PubMed ID: 16895630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of street drug use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-aged women.
    Santoro N; Arnsten JH; Buono D; Howard AA; Schoenbaum EE
    J Womens Health (Larchmt); 2005 Dec; 14(10):898-905. PubMed ID: 16372891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estradiol, FSH and LH profiles in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study.
    Ausmanas MK; Tan DA; Jaisamrarn U; Tian XW; Holinka CF
    Climacteric; 2007 Oct; 10(5):427-37. PubMed ID: 17852146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in collagen expression in cumulus cells after exposure to highly purified menotropin or recombinant follicle-stimulating hormone in a mouse follicle culture model.
    Adriaenssens T; Mazoyer C; Segers I; Wathlet S; Smitz J
    Biol Reprod; 2009 May; 80(5):1015-25. PubMed ID: 19164180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in the immunoreactive and bioactive follicle stimulating hormone content of human urinary menopausal gonadotrophin preparations.
    Rodgers M; McLoughlin JD; Lambert A; Robertson WR; Mitchell R
    Hum Reprod; 1995 Aug; 10(8):1982-6. PubMed ID: 8567826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting reproductive hormones in HIV-infected, substance-using middle-aged women.
    Santoro N; Lo Y; Moskaleva G; Arnsten JH; Floris-Moore M; Howard AA; Adel G; Zeitlian G; Schoenbaum EE
    Menopause; 2007; 14(5):859-65. PubMed ID: 17415019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of intact human follicle-stimulating hormone preparations by reversed-phase high-performance liquid chromatography.
    Loureiro RF; de Oliveira JE; Torjesen PA; Bartolini P; Ribela MT
    J Chromatogr A; 2006 Dec; 1136(1):10-8. PubMed ID: 17049544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
    Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.